Leerink Partnrs Estimates Tourmaline Bio FY2029 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML) – Stock analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for shares of Tourmaline Bio in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings of ($3.15) per share for the year. The consensus estimate for Tourmaline Bio’s current full-year earnings is ($2.99) per share.

TRML has been the subject of a number of other reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price target on shares of Tourmaline Bio in a research note on Wednesday, December 11th. Guggenheim reaffirmed a “buy” rating on shares of Tourmaline Bio in a research note on Wednesday, December 11th. BMO Capital Markets started coverage on shares of Tourmaline Bio in a research report on Friday, December 6th. They issued an “outperform” rating and a $50.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $49.00 price objective on shares of Tourmaline Bio in a research report on Wednesday, December 11th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $54.00.

Tourmaline Bio Trading Down 4.7 %

Shares of NASDAQ:TRML opened at $14.28 on Friday. The company has a 50 day moving average of $20.01 and a 200-day moving average of $21.08. The firm has a market cap of $366.14 million, a P/E ratio of -5.06 and a beta of 2.32. Tourmaline Bio has a twelve month low of $12.12 and a twelve month high of $48.31.

Tourmaline Bio (NASDAQ:TRML) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.06.

Hedge Funds Weigh In On Tourmaline Bio

Hedge funds and other institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC purchased a new stake in Tourmaline Bio during the second quarter valued at about $487,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Tourmaline Bio by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,932 shares of the company’s stock valued at $127,000 after acquiring an additional 1,920 shares in the last quarter. Quest Partners LLC boosted its stake in Tourmaline Bio by 145.4% in the 3rd quarter. Quest Partners LLC now owns 9,381 shares of the company’s stock worth $241,000 after purchasing an additional 5,559 shares during the period. Jennison Associates LLC grew its position in Tourmaline Bio by 2.2% during the 3rd quarter. Jennison Associates LLC now owns 1,151,973 shares of the company’s stock worth $29,617,000 after purchasing an additional 24,282 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Tourmaline Bio by 3.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 63,571 shares of the company’s stock worth $1,634,000 after purchasing an additional 2,147 shares in the last quarter. Institutional investors and hedge funds own 91.89% of the company’s stock.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.